Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinoma

Abstract

Our study aimed to investigate expression and clinical significance of serpin peptidase inhibitor clade A member 3 (SERPINA3) and epidermal growth factor (EGF) containing fibulin-like extracellular matrix protein 2 (EFEMP2) in endometrial carcinoma. A total of 180 patients treated in our hospital from January 2015 to April 2017 were selected as subjects. Positive expression of SERPINA3 was found in 48 cases (80%) in the cancer group, in 6 cases (10%) in the hyperplasia group, and in no case in the control group. The expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia group and control group ( P < 0.05). Positive expression of EFEMP2 was found in 10 cases (16.7%) in the cancer group, in 27 cases (45%) in the hyperplasia group, and in 42 cases (70%) in the control group. The expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups ( P < 0.05). The protein expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia and control groups ( P < 0.05). The protein expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups ( P < 0.05). The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis ( P < 0.05), but not related to age and tumor size ( P > 0.05). SERPINA3 was highly expressed while EFEMP2 was low expressed in endometrial cancer patients. The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis and was hopeful to be one of the detection indexes of endometrial carcinoma.